This grant, offered by the National Cancer Institute (NCI) and participating NIH Institutes, supports discovery research focused on identifying small molecules as chemical probes, therapeutic agents, or immunomodulators. The program aims to uncover validated hits relevant to health outcomes by fostering comprehensive assay development and screening. Covered stages include creating assays for specific biological targets and disease mechanisms, implementing high or moderate throughput screening, and rigorous hit validation using orthogonal assays and cheminformatics. Furthermore, the grant supports hit-to-lead optimization, encompassing structure-activity relationship (SAR) studies, ADME, PK, PD assessments, and in vivo modeling to test efficacy, ultimately advancing promising compounds towards therapeutic applications.
Opportunity ID: 357014
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-25-153 |
| Funding Opportunity Title: | Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.395 — Cancer Treatment Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 06, 2024 |
| Last Updated Date: | Nov 06, 2024 |
| Original Closing Date for Applications: | Sep 07, 2026 |
| Current Closing Date for Applications: | Sep 07, 2026 |
| Archive Date: | Oct 13, 2026 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Native American tribal governments (Federally recognized) For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Small businesses State governments City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts Special district governments Public housing authorities/Indian housing authorities County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for identification of small molecules that function to elucidate the biology of disease as chemical probes or function as agonists or antagonists of disease target(s) for therapy or immunotherapy. The NOFO is intended to support discovery research for the identification of validated hits relevant to health-related outcomes of participating NIH Institutes. Stages of discovery research covered by this NOFO include: 1) assay development for specific biological targets and disease mechanisms relevant to the mission of participating NIH Institutes with the intent to screen for small molecule compounds that show potential as probes for use in advancing knowledge about the known targets, identifying new targets, or as pre-therapeutic leads; 2) screen implementation high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches to identify initial screening hits; 3) hit validation, including implementation of secondary assays that are orthogonal to the primary assay, advanced cheminformatics analysis and initial medicinal chemistry inspection to prioritize the hit set, and follow-up assays to characterize mode and mechanism of action of the validated hits; 4) hit-to-lead optimization, including SAR to optimize target engagement, selectivity and to minimize chemical liabilities, ADME, PK and PD studies, and, if appropriate, in vivo modeling to test efficacy or biological effects. |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/pa-files/PAR-25-153.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 357014 Full Announcement-PAR-25-153 -> PAR-25-153-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-I | Use for due dates on or after January 25, 2025 | PKG00288552 | Jan 05, 2025 | Sep 07, 2026 | View |
Package 1
Mandatory forms
357014 RR_SF424_5_0-5.0.pdf
357014 PHS398_CoverPageSupplement_5_0-5.0.pdf
357014 RR_OtherProjectInfo_1_4-1.4.pdf
357014 PerformanceSite_4_0-4.0.pdf
357014 RR_KeyPersonExpanded_4_0-4.0.pdf
357014 PHS398_ResearchPlan_5_0-5.0.pdf
357014 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
357014 RR_Budget_3_0-3.0.pdf
357014 RR_SubawardBudget30_3_0-3.0.pdf
357014 PHS398_ModularBudget_1_2-1.2.pdf
357014 PHS_AssignmentRequestForm_4_0-4.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
